Hyperfine, Inc. (HYPR)
NASDAQ: HYPR · Real-Time Price · USD
1.480
+0.070 (4.96%)
May 20, 2026, 4:00 PM EDT - Market closed
Hyperfine Revenue
Hyperfine had revenue of $3.90M in the quarter ending March 31, 2026, with 82.64% growth. This brings the company's revenue in the last twelve months to $15.33M, up 30.66% year-over-year. In the year 2025, Hyperfine had annual revenue of $13.56M with 5.22% growth.
Revenue (ttm)
$15.33M
Revenue Growth
+30.66%
P/S Ratio
9.51
Revenue / Employee
$150,284
Employees
102
Market Cap
145.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.56M | 673.00K | 5.22% |
| Dec 31, 2024 | 12.89M | 1.86M | 16.84% |
| Dec 31, 2023 | 11.03M | 4.22M | 61.90% |
| Dec 31, 2022 | 6.81M | 5.32M | 355.48% |
| Dec 31, 2021 | 1.50M | 1.20M | 408.84% |
| Dec 31, 2020 | 294.00K | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Inogen | 351.50M |
| Treace Medical Concepts | 207.32M |
| Quanterix | 144.98M |
| Owlet | 107.06M |
| AVITA Medical | 72.35M |
| CVRx, Inc. | 59.07M |
| Apyx Medical | 55.90M |
| SANUWAVE Health | 44.34M |
HYPR News
- 5 days ago - Hyperfine management to meet virtually with Lake Street - TheFly
- 5 days ago - Hyperfine management to meet virtually with Oppenheimer - TheFly
- 7 days ago - Hyperfine price target raised to $2 from $1.60 at B. Riley - TheFly
- 8 days ago - Hyperfine Q1 Earnings Call Highlights - MarketBeat
- 8 days ago - Hyperfine reports Q1 EPS (9c), consensus (9c) - TheFly
- 8 days ago - Hyperfine still sees FY26 revenue $20M-$22M, consensus $20.04M - TheFly
- 8 days ago - Hyperfine files to sell 1.08M shares of Class A common stock for holders - TheFly
- 8 days ago - Hyperfine Earnings Call Transcript: Q1 2026 - Transcripts